Volume 4, Issue 4 (Autumn 2015)                   J Occup Health Epidemiol 2015, 4(4): 223-228 | Back to browse issues page


XML Print


1- Dept. of Chemistry, Payame Noor University, P.O. Box, 19395-3697, Tehran, Iran. , a.amiri@pnu.ac.ir
2- Dept. of Chemistry, Payame Noor University, P.O. Box, 19395-3697, Tehran, Iran
Article history
Received: 2016/06/30
Accepted: 2016/10/8
ePublished: 2016/11/9
Abstract:   (6237 Views)

Background: Cadmium (Cd) is an extremely toxic metal and environmental exposure to Cd has been particularly problematic in the world. Oral exposure to Cd may result in adverse effects on a number of tissues, the immune system, and the cardiovascular system. Compounds containing Cd are also carcinogenic. The presence of Cd in drinking water resources in the southeastern region of Rafsanjan plain (Iran) at concentrations greater than acceptable limits may result in various adverse health effects. The aim of this research was to test the chelation potency of deferasirox (DFS or ICL670), a tridentate metal chelator, and deferiprone (L1), a bidentate metal chelator, in the mobilization of Cd in Cd-exposed rats as a biological model.

Materials and Methods: Male Wistar rats were exposed to 40 mg/kg body weight of cadmium chloride in drinking water for 6 weeks, followed by treatment with DFS (100 mg/kg body weight, oral, once daily) and L1 (100 mg/kg body weight, oral, once daily), alone or in combination, for 7 consecutive days. After chelation therapy, the rats were anesthetized by ether vapor and immobilized by cervical dislocation. Then, their heart, liver, kidneys, intestine, and blood were sampled for clinical hematological variables and determination of Cd and Fe concentration by inductively coupled plasma optical emission spectrometry (ICP-OES). The data were subjected to statistical analysis using Student’s t-test. All Ρ values of less than 0.05 were considered significant.

Results: The results show that both chelators (DFS and L1) increase the removal of Cd from the tissues. No effects of Cd or any of the two treatments (L1 or DFS) were observed on white blood cell (WBC) count, red blood cell (RBC) count, and hemoglobin‎ (Hb) level.

Conclusions: The comparison of single and combined therapy showed that the combined chelation therapy (DFS + L1) was more effective in depleting Cd concentration in soft tissues.

Full-Text [PDF 299 kb]   |   Full Text (HTML)   (1747 Downloads)    

References
1. Nordberg GF. Biomarkers of exposure, effects and susceptibility in humans and their application in studies of interactions among metals in China. Toxicol Lett 2010; 192(1):45-9.
2. Zalups RK, Ahmad S. Molecular handling of cadmium in transporting epithelia. Toxicol Appl Pharmacol 2003; 186(3):163-88.
3. Matovic V, Buha A, Bulat Z, Dukic-Cosic D. Cadmium toxicity revisited: focus on oxidative stress induction and interactions with zinc and magnesium. Arh Hig Rada Toksikol 2011; 62(1):65-76.
4. Malakootian M, Darabi-Fard Z, Amirmahani N, Nasiri A. Evaluation of arsenic, copper, lead, cadmium, and iron concentration in drinking water resources of central and southern Bardsir plain, Iran, in 2014. Journal of Kerman University of Medical Sciences 2015; 22(5): 542-54.
5. Malakootian M, Mobini M, Sharifi I, Haghighi Fard A. Evaluation of corrosion and scaling potential of wells drinking water and aqueducts in rural areas adjacent to Rafsanjan fault in during october to december 2013. Journal of Rafsanjan University of Medical Sciences 2014; 13(3):293-304.
6. Waters RS, Bryden NA, Patterson KY, Veillon C, Anderson RA. EDTA chelation effects on urinary losses of cadmium, calcium, chromium, cobalt, copper, lead, magnesium, and zinc. Biol Trace Elem Res 2001; 83(3):207-21.
7. Kelley C. Cadmium therapeutic agents. Curr Pharm Des 1999; 5(4):229-40.
8. Tandon SK, Prasad S, Singh S. Chelation in metal intoxication: influence of cysteine or N-acetyl cysteine on the efficacy of 2, 3-dimercaptopropane-1-sulphonate in the treatment of cadmium toxicity. J Appl Toxicol 2002; 22(1):67-71.
9. Bamonti F, Fulgenzi A, Novembrino C, Ferrero ME. Metal chelation therapy in rheumathoid arthritis: a case report. Successful management of rheumathoid arthritis by metal chelation therapy. Biometals 2011; 24(6):1093-8.
10. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, et al. Randomized phase II trial of deferasirox (Exjade, ICL 670), a once-daily, orally administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91(7):873-80.
11. Amiri A, Fatemi SJ, Fatemi SN. Removal of thallium by combining desferrioxamine and deferiprone chelators in rats. Biometals 2007; 20(2):159-63.
12. Fatemi SJ, Tubafard S, Nadi B. Evaluation of the effect of cadmium on rat organs and investigation of diethyl carbamate as an oral drug in treatment of cadmium toxicity. Med Chem Res 2009; 18(3):179-86.
13. Voskaridou E, Christoulas D, Terpos E. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting sever iron overload after single-agent chelation therapies. Br J Haematol 2011; 154(5):654-6.
14. Hershko C, Konijn AM, Nick HP, Breuer W, Cabatchik ZI, Link G. ICL670A: a new synthetic oral chelator: evaluation in hyper transfused rats with selective radio iron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cell in culture. Blood 2001; 97(4):1115-22.
15. Steinhauser S, Heinz U, Bartholoma M, Weyhermuller T, Nick H, Hegetschweiler K. Complex formation of ICL670 and related ligands with Fe-III and Fe-II. Berichte der deutschen chemischen Gesellschaft 2004; 21:4177-92.
16. Luparello C, Sirchia R, Longo A. Cadmium as a transcriptional modulator in human cells. Crit Rev Toxicol 2011; 41(1):75-82.
17. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006; 107(9):3436-41.
18. Wan L, Zhang H. Cadmium toxicity: effects on cytoskeleton, vesicular trafficking and cell wall reconstruction. Plant Signal Behav 2012; 7(3):345-8.

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.